About Synthetic Genomics
Synthetic Genomics is a company based in San Diego (United States) founded in 2005. Synthetic Genomics has raised $75 million across 4 funding rounds from investors including HHS, Biotechonomy and Draper Frontier. The company has 190 employees as of December 31, 2022. Synthetic Genomics has completed 1 acquisition, including Febit. Synthetic Genomics offers products and services including Algae Biofuel. Synthetic Genomics operates in a competitive market with competitors including Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.
- Headquarter San Diego, United States
- Employees 190 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Synthetic Genomics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Synthetic Genomics
Synthetic Genomics offers a comprehensive portfolio of products and services, including Algae Biofuel.
Optimizes microalgae to create renewable oil for decarbonizing transportation.
People of Synthetic Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of Synthetic Genomics
Synthetic Genomics has successfully raised a total of $75M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $387.63 thousand completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Synthetic Genomics
Synthetic Genomics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Biotechonomy and Draper Frontier.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Seed & early-stage micro VC firm investing in the US
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Synthetic Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Synthetic Genomics
Synthetic Genomics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Febit.
Investment portfolio details for Synthetic Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Geniom platform and services are provided for genomic researchers.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Synthetic Genomics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Synthetic Genomics
Detailed financials for Synthetic Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Synthetic Genomics Comparisons
Peer comparison for Synthetic Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Synthetic Genomics
Synthetic Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
Detailed competitors of Synthetic Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synthetic Genomics
Complete news archive for Synthetic Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synthetic Genomics
Synthetic Genomics was founded in 2005.
Synthetic Genomics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Synthetic Genomics is a funded company, having raised a total of $75M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Synthetic Genomics is 190.
Synthetic Genomics (SGI) engages in synthesizing and programming DNA by developing and utilizing the technologies in synthetic genomics. SGI provides solutions to three end markets: research, bioproduction and applied products. Its research segment is focused on genomics solutions for academic and commercial RD organizations. Its commercial products and services include instrumentation, reagents, DNA synthesis services, and bioinformatics services and software. In 2015, the company launched the BioXP 3200 system, a benchtop DNA printer that takes sequencing data and produces high-quality DNA fragments. It is also focussed on improving existing production hosts and developing new synthetic production hosts for new and more efficient routes to bioproducts including materials, chemicals, energy and other goods derived from renewable biological resources.
Synthetic Genomics's top competitors include Syngenta, Sutro Biopharma and Avidity Biosciences.
Synthetic Genomics offers Algae Biofuel.
Synthetic Genomics has made 1 acquisition, including Febit.
Synthetic Genomics has 3 investors. Key investors include HHS, Biotechonomy, and Draper Frontier.